title: Biological markers in the etiology of psoriasis: Targeted treatment options.
abstract: Psoriasis is a common chronic and disabling inflammatory disease that has an enormous physical, functional and psychosocial impact on patients' quality of life. To date several conventional therapies are available for the treatment of this condition (eg, cyclosporine, methotrexate, retinoids, and psoralen plus ultraviolet A) which, although providing clinical response, do not maintain long-lasting disease remission and at times show poor tolerability with potential toxicity thus limiting their use. A challenge in psoriasis management is to utilize precociously an adequate therapy and to achieve effective and safe maintenance of its clearance by improving both skin and joint manifestations as well as to prevent joint destruction and disability. Recent improvement in the knowledge of the pathogenesis of this disease was fundamental for the development of novel targeted treatment options that may be effective, safer and well tolerated on long-term administration periods, thus improving patient's quality of life. These novel agents, which are called "biologics", target specifically tumor necrosis factor-alpha (infliximab, etanercept and adalimumab) or T cells (alefacept and efalizumab).
authors.affiliation: San Gallicano Dermatological Institute, Rome, Italy.
authors.forename: Catia
authors.initials: C
authors.lastname: de Felice
authors.forename: Georgiana Clare
authors.initials: GC
authors.lastname: Marulli
authors.forename: Marco
authors.initials: M
authors.lastname: Ardigò
authors.forename: Enzo
authors.initials: E
authors.lastname: Berardesca
references.citation: J Am Acad Dermatol. 2006 Mar;54(3 Suppl 2):S85-91
references.pmid: 16488334
references.citation: J Invest Dermatol. 1999 Nov;113(5):752-9
references.pmid: 10571730
references.citation: Dermatol Ther. 2004;17(5):341-9
references.pmid: 15379769
references.citation: Health Technol Assess. 2000;4(40):1-125
references.pmid: 11207450
references.citation: Clin Exp Immunol. 1994 Apr;96(1):146-51
references.pmid: 8149659
references.citation: J Eur Acad Dermatol Venereol. 2003 Jul;17 Suppl 2:12-6
references.pmid: 12795770
references.citation: N Engl J Med. 2003 Nov 20;349(21):2014-22
references.pmid: 14627786
references.citation: Rev Gastroenterol Disord. 2004 Fall;4(4):196-210
references.pmid: 15580154
references.citation: Arthritis Rheum. 2005 Oct;52(10):3279-89
references.pmid: 16200601
references.citation: J Am Acad Dermatol. 2006 Mar;54(3 Suppl 2):S92-100
references.pmid: 16488335
references.citation: J Am Acad Dermatol. 2006 Mar;54(3 Suppl 2):S81-4
references.pmid: 16488333
references.citation: Hum Mol Genet. 1998;7(10):1537-45
references.pmid: 9735374
references.citation: J Am Acad Dermatol. 2002 Dec;47(6):821-33
references.pmid: 12451365
references.citation: Br J Dermatol. 2005 Jun;152(6):1304-12
references.pmid: 15948997
references.citation: J Am Acad Dermatol. 2007 Apr;56(4):598-603
references.pmid: 17113190
references.citation: Dermatol Ther. 2004;17(5):376-82
references.pmid: 15379772
references.citation: J Am Acad Dermatol. 2006 Mar;54(3 Suppl 2):S67-80
references.pmid: 16488332
references.citation: Arch Dermatol. 2003 Jun;139(6):719-27
references.pmid: 12810502
references.citation: Ann Rheum Dis. 2005 Mar;64 Suppl 2:ii87-90; discussion ii91-2
references.pmid: 15708946
references.citation: Br J Dermatol. 2000 Mar;142(3):401-12
references.pmid: 10735943
references.citation: Dermatology. 2004;208(4):297-306
references.pmid: 15178911
references.citation: J Am Acad Dermatol. 2007 Jan;56(1):31.e1-15
references.pmid: 17097378
references.citation: Arch Dermatol Res. 2006 Jun;298(1):7-15
references.pmid: 16691429
references.citation: J Am Acad Dermatol. 2005 Mar;52(3 Pt 1):425-33
references.pmid: 15761420
references.citation: Annu Rev Immunol. 1992;10:411-52
references.pmid: 1590993
references.citation: J Eur Acad Dermatol Venereol. 2003 Jul;17 Suppl 2:1-5
references.pmid: 12795768
references.citation: J Eur Acad Dermatol Venereol. 2003 May;17(3):257-70
references.pmid: 12702062
references.citation: Arthritis Rheum. 2005 Apr;52(4):1227-36
references.pmid: 15818699
references.citation: Lancet. 2005 Oct 15-21;366(9494):1367-74
references.pmid: 16226614
references.citation: Arch Dermatol. 2005 Jan;141(1):31-8
references.pmid: 15655139
references.citation: J Dtsch Dermatol Ges. 2006 Nov;4(11):947-56
references.pmid: 17081270
references.citation: J Am Acad Dermatol. 1984 Nov;11(5 Pt 2):937-47
references.pmid: 6389615
references.citation: Br J Dermatol. 2006 Jul;155(1):170-81
references.pmid: 16792770
references.citation: Br J Dermatol. 2005 Sep;153(3):486-97
references.pmid: 16120132
references.citation: Immunity. 2004 May;20(5):539-50
references.pmid: 15142523
references.citation: N Engl J Med. 2001 Jul 26;345(4):248-55
references.pmid: 11474662
references.citation: J Investig Dermatol Symp Proc. 2004 Mar;9(2):136-9
references.pmid: 15083780
references.citation: J Invest Dermatol. 2004 Mar;122(3):602-7
references.pmid: 15086541